Targeted endovenous treatment of Giacomini vein insufficiency-associated varicose disease: considering the reflux patterns

PURPOSE

We aimed to assess the technical feasibility of targeted endovenous treatment of Giacomini vein insufficiency (GVI)-associated varicose disease and report our early results.

METHODS

We retrospectively screened 335 patients with varicose disease who underwent endovenous laser ablation from September 2011 to January 2013, and determined 17 patients who underwent Giacomini vein ablation. Using a targeted endovenous treatment approach considering the reflux pattern, all healthy great saphenous veins (GSV) or vein segments were preserved while all insufficient veins (Giacomini vein, perforator veins, small saphenous vein, anterior accessory GSV, major tributary veins, or incompetent segments of the GSV) were ablated. Treatment success was analysed using Doppler findings and clinical assessment scores before and after treatment.

RESULTS

Targeted endovenous treatment was technically successful in all cases. Seven GSVs were preserved totally and three GSVs were preserved partially (10/17, 58%), with no major complications. Clinical assessment scores and Doppler findings were improved in all cases.

CONCLUSION

Targeted endovenous treatment of GVI-associated varicose disease is safe and effective. In majority of GVI cases saphenous vein can be preserved using this approach.The Giacomini vein (GV) is defined as a branch of cranial extension of the small saphenous vein (SSV) that connects the SSV with the posterior thigh circumflex vein (PTCV) (1). In 14% of the population, SSV continues directly as the GV (2). Although most varices are caused by reflux originating from the great saphenous vein (GSV), SSV, or accessory saphenous branches, varicose disease caused by a Giacomini vein insufficiency (GVI) is not a rare condition (3, 4). GVI is commonly seen with varices that arise on the posterior thigh or calf and accounts for 4%–6% of cases treated by endovenous laser ablation (ELA) (5–8). There is no defined standard treatment for GVI-associated varicose disease. Performing a phlebectomy as the only treatment may result in recurrent varicose disease for some patients. Classical saphenous vein-focused surgical therapies may result in overtreatment or undertreatment. Targeted endovenous treatment (TET) differs from surgical treatments by focusing on the reflux sources and preserving healthy GSV, either totally or partially, while ablating insufficient segments of the vein. The ablation may be applied to any vein including the GV, perforator vein, SSV, and anterior accessory GSV, except the deep veins.ELA has recently evolved into an accepted option for eliminating truncal reflux for an incompetent GSV or SSV, with successful saphenous vein ablation rates ranging from 88% to 100% (9–12). However, reports of ELA treatment of the GVI are rare (3, 4, 7, 13). Some authors recommend only GSV ablation (4), while others ablate the insufficient GV (3). To the best of our knowledge, there is only one study on treatment of GVI considering the reflux pattern, which used both ELA and sclerotherapy (13). The present study focuses on the saphenous vein sparing effect of TET while treating the GVI by ELA and sclerotherapy.Today, reflux sources other than the saphenous veins, such as the perforator veins or GVs, are also accessible and can be treated selectively with the help of new endovenous techniques. TET considering the various reflux patterns is a minimally invasive and selective treatment method for GVI that may prevent unnecessary saphenous ablations in some cases. The purpose of this study was to evaluate the technical feasibility of TET and report early treatment results of 17 patients who had GVI with various reflux sources.